Overview

Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus

Status:
Completed

Trial end date:
2014-04-01

Target enrollment:

Participant gender:

Summary

To compare the effect on glycemic control (HbA1c) of exenatide suspension administered once weekly to that achieved by sitagliptin or placebo administered once daily for 28 weeks in subjects with type 2 diabetes mellitus.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Exenatide
Sitagliptin Phosphate